- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
AJMC® in the Press, October 15, 2021
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
A letter by the editor-in-chief of The Daily Toreador referenced an article published on AJMC.com, the website of The American Journal of Managed Care® (AJMC®). The article, “FDA's Revised Blood Donation Guidance for Gay Men Still Courts Controversy,” addressed an announcement by the FDA that changed wait time restrictions on gay men being allowed to donate blood from 1 year to 3 months amid the pandemic.
An article by Sports Illustrated mentioned AJMC.com’s coverage of findings presented at the American Diabetes Association’s 80th Scientific Sessions. The piece, "Racial Disparities Persist in Maternal Morbidity, Mortality and Infant Health," noted that American women die in childbirth at a higher rate than in any other developed country, with non-Hispanic Black women found to be more than 3 times more likely to have a maternal death than White women in the United States.
An opinion piece in The San Bernardino Sun cited a study published in the July 2021 issue of AJMC®, titled “Reduced Medical Spending Associated With Integrated Pharmacy Benefits.” In the study, Blue Cross and Blue Shield of Louisiana members covered by an integrated pharmacy benefit, as opposed to a pharmacy carve-out, experienced slower growth in medical spending.
Unique Psychological Burden of Fear of Progression Seen in MG
August 6th 2025Fear of progression is common among patients living with chronic diseases, but the degree to which it interferes with patient outcomes, including treatment adherence, deserves further investigation, study authors note.
Read More
Taletrectinib Recommended in NCCN Guidelines for ROS1-Positive NSCLC
July 31st 2025Taletrectinib was added to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology as a preferred option for the first-line and subsequent treatment of advanced ROS1-positive non–small cell lung cancer (NSCLC).
Read More
